Perimyocarditis Following COVID-19 Vaccination

Tinoco, M; Leite, Sérgio; Faria, Bebiana; Cardoso, Sara; Hafe, Pedro von; Dias, G; Cardoso, Filipa; Pereira, Tâmara; Machado, Inocência; Lourenço, António

doi:10.1177/11795468211056634

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found around 25 studies that met our criteria. After excluding duplication, we finally included 14 published articles in our study, which consists of 40 case reports (Table 1) [1,[5][6][7][8][9][10][11][12][13][14][15][16][17] of myocarditis after receiving the COVID-19 vaccine.…”

Section: Eligibility Criteriamentioning

confidence: 99%

“…Unusual dyspnea, palpitations, chest discomfort with or without elevated troponin, arrhythmia, syncope, acute or chronic congestive heart failure, aborted abrupt cardiac death, and fulminant cardiogenic shock are all red flags [31]. A majority of cases of myocarditis following COVID-19 vaccination were reported two to three days after receiving the second dose of mRNA vaccination; all of the patients in these reports complained of chest pain [17]. Our analysis results also showed that the majority of patients presented with complaints of chest pain or shortness of breath within an average of 5.09 days (±14.04 days) after the administration of the COVID-19 vaccine.…”

Section: Table 3: Components Of Pfizer Versus Moderna Vaccine Versus Janssenmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

Chen¹,

Ikwuanusi²,

Bommu³

et al. 2022

Cureus

View full text Add to dashboard Cite

After the surging rise in the Coronavirus disease 2019 (COVID-19) pandemic, the Food and Drug Administration (FDA) approved emergency approval of vaccinations to prevent life-threatening complications of COVID-19 infection. These vaccines are BNT162b2, mRNA-1273. Later, the FDA also approved JNJ-78436735. COVID-19 vaccination does not have major side effects, but there are some concerning adverse events reported right after vaccination. Myocarditis is one of them. Based on our analysis of 40 case reports, we are presenting the epidemiology and clinical picture of myocarditis related to the COVID-19 vaccine.Based on our analysis, we found that the majority of cases were seen in males with 90% predominance, and these cases were seen in the age group of 29.13 years old (mean, SD of 14.39 years). In 65% of cases, patients took the BNT162b2 vaccine; 30% of cases were reported with the mRNA-1273 vaccine; and 5% of cases with JNJ-78436735. Of all the cases, 80% of them are reported after the second dose of the vaccine with either Moderna or Pfizer.The characteristics of COVID-19 vaccine-related myocarditis were analyzed in this study. We identified several findings, ranging from age, gender, type of vaccination, presentation of symptoms, and diagnosis modality. This depicts the picture of COVID-19 vaccine-related myocarditis and what physicians should expect when dealing with the disease. Our analysis showed that more cases were reported after receiving the BNT162b2 vaccine compared to mRNA-1273 and JNJ-78436735 vaccines. Further research needs to be conducted to analyze the underlying cause of this association.

show abstract

Section: Eligibility Criteriamentioning

confidence: 99%

Section: Table 3: Components Of Pfizer Versus Moderna Vaccine Versus Janssenmentioning

confidence: 99%

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

Chen¹,

Ikwuanusi²,

Bommu³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Moreover, some warn that the immunity which is expected to be provided by vaccines decreases after a while, and therefore, vaccines may not be fully reliable (Yewdell, 2021). While the booster doses are indeed administrated in several countries, the reports of medical problems after vaccination (Tinoco et al, 2021;Al-Midfai et al, 2022;Chen et al, 2022;Fathy et al, 2022;Sriwastava et al, 2022) alarm that the current vaccines may not be wholesome in the long term. Considering the aforementioned conditions, the development of novel specific anti-COVID19 therapeutics seems to be a compelling urge for pandemic eradication.…”

Section: Introductionmentioning

confidence: 99%

Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches

2022

View full text Add to dashboard Cite

The SARS-CoV-2, the virus which is responsible for COVID-19 disease, employs its spike protein to recognize its receptor, angiotensin-converting enzyme 2 (ACE2), and subsequently enters the host cell. In this process, the receptor-binding domain (RBD) of the spike has an interface with the α1-helix of the peptidase domain (PD) of ACE2. This study focuses on the disruption of the protein-protein interaction (PPI) of RBD-ACE2. Among the residues in the template (which was extracted from the ACE2), those with unfavorable energies were selected for substitution by mutagenesis. As a result, a library of 140 peptide candidates was constructed and the binding affinity of each candidate was evaluated by molecular docking and molecular dynamics simulations against the α1-helix of ACE2. Finally, the most potent peptides P23 (GFNNYFPHQSYGFMPTNGVGY), P28 (GFNQYFPHQSYGFPPTNGVGY), and P31 (GFNRYFPHQSYGFCPTNGVGY) were selected and their dynamic behaviors were studied. The results showed peptide inhibitors increased the radius, surface accessible area, and overall mobility of residues of the protein. However, no significant alteration was seen in the key residues in the active site. Meanwhile, they can be proposed as promising agents against COVID-19 by suppressing the viral attachment and curbing the infection at its early stage. The designed peptides showed potency against beta, gamma, delta, and omicron variants of SARS-CoV-2.

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

Perimyocarditis Following COVID-19 Vaccination

Cited by 6 publications

References 9 publications

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

COVID-19 Vaccine-Related Myocarditis: A Descriptive Study of 40 Case Reports

Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches

Tozinameran

Contact Info

Product

Resources

About